(1H-Benzoimidazol-2-yl)(2,6-dichlorophenyl)isopropylamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (1H-Benzoimidazol-2-yl)(2,6-dichlorophenyl)isopropylamine
• 英文别名: N-(2,6-dichlorophenyl)-N-propan-2-yl-1H-benzimidazol-2-amine
• 化学式: C₁₆H₁₅Cl₂N₃
• 分子量: 320.221
• InChiKey: YQBVIBNCJKGKDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  31.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴丙烷 、 N-(2,6-dichlorophenyl)-1H-benzo[d]imidazole-2-amine 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 1.0h， 生成 (1H-Benzoimidazol-2-yl)(2,6-dichlorophenyl)isopropylamine
  参考文献：
  名称：

  [DE] N-SUBSTITUIERTE (BENZOIMIDAZOL-2-YL)-PHENYL-AMINE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS MEDIKAMENT ODER DIAGNOSTIKUM SOWIE SIE ENTHALTENDES MEDIKAMENT
  [EN] N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES
  [FR] (BENZOIMIDAZOL-2-YL)-PHENYLAMINES N-SUBSTITUEES, LEUR PROCEDE DE PRODUCTION, LEUR UTILISATION COMME MEDICAMENT OU AGENT DIAGNOSTIC, ET MEDICAMENT LES CONTENANT

  摘要：

  该发明涉及式(I)的连接物，其中R1至R7具有在权利要求中所表示的含义。含有此类连接物的药物在预防或治疗各种疾病方面是有用的。因此，这些连接物可以用于肾脏疾病（如急性或慢性肾衰竭）、胆功能障碍、呼吸障碍（如打鼾或睡眠呼吸暂停）或中风等方面。

  公开号：

  WO2004069811A1

文献信息

• N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
  申请人：Heinelt Uwe

  公开号：US20050054705A1

  公开（公告）日：2005-03-10

  This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic renal failure, disorders of biliary function and for respiratory disorders such as snoring or sleep apnea or for stroke.

  本发明涉及式(I)的化合物，包含该化合物的组合物，用于抑制亚型3的钠-质子交换体（NHE3），对于患有疾病状态的患者预防或治疗各种疾病，例如肾脏疾病，包括急性或慢性肾衰竭，胆汁功能障碍和呼吸系统疾病，例如打鼾或睡眠呼吸暂停或中风。
• N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them
  申请人：HEINELT Uwe

  公开号：US20080167359A1

  公开（公告）日：2008-07-10

  This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic renal failure, disorders of biliary function and for respiratory disorders such as snoring or sleep apnea or for stroke.

  本发明涉及化合物I的配方，包含该化合物的组合物，用于抑制亚型3（NHE3）的钠-质子交换器，对于患有疾病状态的患者预防或治疗各种疾病是有用的，例如肾功能障碍，包括急性或慢性肾功能衰竭，胆汁功能障碍以及呼吸障碍，如打鼾或睡眠呼吸暂停或中风。
• N-substituted (benzoimidazol-2-yl)phenylamines, processes for their preparation, their use as a medicament or diagnostic aid, and a medicament comprising them
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US08067614B2

  公开（公告）日：2011-11-29

  This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic renal failure, disorders of biliary function and for respiratory disorders such as snoring or sleep apnea or for stroke.

  本发明涉及化合物I的配方，包含该化合物的组合物，用于抑制亚型3的钠-质子交换器（NHE3），这些组合物对于患有疾病状态的患者的预防或治疗是有用的，例如肾功能障碍，包括急性或慢性肾衰竭，胆汁功能障碍以及呼吸系统障碍，如打鼾或睡眠呼吸暂停，或中风。
• N-SUBSTITUIERTE (BENZOIMIDAZOL-2-YL)-PHENYL-AMINE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS MEDIKAMENT ODER DIAGNOSTIKUM SOWIE SIE ENTHALTENDES MEDIKAMENT
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1592671B1

  公开（公告）日：2008-04-09
• N-desmethyl levomepromazine
  申请人：Moore A. Keith

  公开号：US20050080076A1

  公开（公告）日：2005-04-14

  A pharmaceutically active N-desmethyl levomepromazine (abbreviated NDM LMP) and method of use. NDM LMP has substantially the same therapeutic effects as the parent levomepromazine but is subject to less disposition (e.g. presystemic and systemic metabolism) and thus has improved properties over the parent.